Quarterly ResultAug 5, 2026, 07:37 AM
Royalty Pharma Q2 Portfolio Receipts $773M; Raises FY26 Guidance
AI Summary
Royalty Pharma plc reported strong financial results for the second quarter of 2026, with Portfolio Receipts increasing 6% to $773 million and Royalty Receipts growing 14% to $768 million. Driven by this performance, the company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3,400 million to $3,500 million. Royalty Pharma also highlighted significant transaction activity, including the acquisition of a royalty on AstraZeneca’s cliramitug for up to $425 million, contributing to over $1 billion in Capital Deployment year-to-date.
Key Highlights
- Raised full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million.
- Q2 2026 Portfolio Receipts increased 6% to $773 million.
- Q2 2026 Royalty Receipts grew 14% to $768 million.
- Net cash provided by operating activities was $728 million in Q2 2026.
- Acquired royalty on AstraZeneca’s cliramitug for up to $425 million.
- Total Capital Deployment reached over $1 billion so far in 2026.
- Adjusted EBITDA (non-GAAP) was $736 million in Q2 2026.
- Repurchased 0.9 million Class A ordinary shares for $45 million in Q2.
Price Impact
More from RPRX